反应详情

Using 4-{2-[bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid (4-iodo-phenyl)-amide (25 mg) obtained in Step A in Example 1-D-65 and 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (13 mg) instead of pyridin-3-boronic acid, in the same manner as Step B in Example 1-D-65, 4-{2-[bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidine-7-carboxylic acid-4-pyridin-4-yl-phenyl)-amide was obtained. Further, in the same manner as Step B in Example 1-D-65 according to the above Deprotection method 3, the PMB groups were removed, to obtain the desired compound (D-66) as a colorless solid (8.9 mg, 40%).

1. customthe PMB groups were removed